Market Size of Hemoglobinopathies Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 7.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Hemoglobinopathies Treatment Market Analysis
The global hemoglobinopathies treatment market was studied and projected to grow with a CAGR of nearly 7% over the forecast period. The growth is primarily due to an increase in the cases of hemoglobinopathies, coupled with growing awareness pertaining to hemoglobin disorders. According to the World Health Organization, about 1.1% of the couples globally are at the risk of having a child with hemoglobin disorder and prevalence was estimated at 2.55 per 1000. In addition, the presence of strong product pipeline for the treatment of hemoglobinopathies and continuous efforts from the market players and government in developing the new therapies for the same are anticipated to boost the market growth. However, low awareness related to the hemoglobinopathies in low and some of the middle-income countries is anticipated to hamper the market growth. Moreover, the initiatives such as newborn screening for detection of potential disorders are lead by the government and private organizations are anticipated to fuel the market growth for hemoglobinopathies treatment.
Hemoglobinopathies Treatment Industry Segmentation
As per the scope of the report, hemoglobinopathies is the group of blood disorders which are inheritable, including thalassemia, sickle cell anaemia and others.
| By Treatment | |
| Stem Cell Therapy | |
| Blood Transfusion | |
| Iron Chelation Therapy | |
| Others |
| By Application | |
| Thalassemia | |
| Sickle Cell Anaemia | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Hemoglobinopathies Treatment Market Size Summary
The hemoglobinopathies treatment market is poised for significant growth, driven by an increasing prevalence of hemoglobin disorders and heightened awareness of these conditions. The market is supported by a robust pipeline of therapeutic products and ongoing efforts from both industry players and governmental bodies to develop new treatment modalities. Despite these advancements, the market faces challenges in regions with low awareness, particularly in some low and middle-income countries. Initiatives such as newborn screening programs, spearheaded by both government and private organizations, are expected to further propel market expansion. The treatment landscape includes a variety of approaches, from drug therapies like antibiotics and analgesics to more advanced interventions such as blood transfusions and stem cell therapy. Additionally, research into gene therapies is contributing to the market's dynamic growth.
Regionally, Europe is expected to experience substantial market growth, particularly in Mediterranean countries, due to a high incidence of hemoglobinopathies and increased awareness. North America is also anticipated to see notable growth, supported by a well-established healthcare infrastructure and proactive awareness initiatives. The global market is moderately fragmented and competitive, with key players focusing on product innovation, new launches, and geographical expansion. Collaborations, such as the one between Sangamo Therapeutics and Pfizer for hemophilia A gene therapy, highlight the industry's commitment to advancing treatment options. Prominent companies in the market include Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc., EMI Holding, Inc., and Celgene Corporation, all of which are actively contributing to the market's development.
Hemoglobinopathies Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Genetic Blood Disorders
-
1.2.2 Presence of Robust Pipeline
-
-
1.3 Market Restraints
-
1.3.1 Low Awareness Regarding Hemoglobinopathies
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Treatment
-
2.1.1 Stem Cell Therapy
-
2.1.2 Blood Transfusion
-
2.1.3 Iron Chelation Therapy
-
2.1.4 Others
-
-
2.2 By Application
-
2.2.1 Thalassemia
-
2.2.2 Sickle Cell Anaemia
-
2.2.3 Others
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Hemoglobinopathies Treatment Market Size FAQs
What is the current Hemoglobinopathies Treatment Market size?
The Hemoglobinopathies Treatment Market is projected to register a CAGR of 7% during the forecast period (2024-2029)
Who are the key players in Hemoglobinopathies Treatment Market?
Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc., EMI Holding, Inc. and Celgene Corporation are the major companies operating in the Hemoglobinopathies Treatment Market.
